Larry Ellison Cancels Plan To Sell Oracle Stock

Larry Ellison cancels plan to sell Oracle stock; Oracle said no shares were sold, removing an immediate insider-selling overhang for investors.

September 12, 2026·2 min read
View all news articles
Flat vector server core dimming symbolizing Larry Ellison cancels plan to sell Oracle stock with subtle shadow

KEY TAKEAWAYS

  • Ellison canceled his Rule 10b5-1 plan and Oracle said no shares were sold under it.
  • A regulatory filing had shown adoption on June 22 authorizing up to 50 million shares.
  • The cancellation removes an immediate insider-selling overhang for investors.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Oracle said in a press release on Sept. 12, 2026, that Larry Ellison canceled a plan to sell Oracle stock. The company confirmed no shares were sold under the Rule 10b5‑1 trading arrangement and that Ellison has no other plans to sell his Oracle shares, easing investor concern about a large insider sale.

Ellison Cancels 10b5‑1 Plan

Larry Ellison, Oracle’s Executive Chair of the Board and Chief Technology Officer, canceled his Rule 10b5‑1 plan to sell Oracle stock, the company said. The release stated no shares were sold under the plan and Ellison has no other plans to sell his holdings. Oracle’s brief statement focused on these points without further explanation. [source:1]

Plan Parameters and SEC Filing

A regulatory filing published on Sept. 11, 2026, disclosed that Ellison adopted the Rule 10b5‑1 trading plan on June 22, 2026. The plan authorized potential sales of up to 50 million Oracle shares, valued at about $7.5 billion at contemporaneous prices, and set a scheduled end date of Oct. 24, 2026. [source:10][source:11]

Rule 10b5‑1 plans are prearranged trading programs that allow insiders to sell shares according to a preset schedule. They aim to protect insiders from allegations of trading on material nonpublic information if the plan is established in good faith.

Investor Context and Implications

Ellison has historically sold only modest volumes of Oracle stock, with reports noting he has not sold more than 25,000 shares at a time this century. The newly disclosed plan’s authorization to sell up to 50 million shares was unusually large compared with his past behavior.

The cancellation removes the immediate prospect of a large scheduled insider sale, easing the near-term overhang that had drawn investor attention.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

Anthropic Slow AI Development Pledge

Anthropic Slow AI Development Pledge

Anthropic slow AI development pledge to embed third-party evaluators could spur governance-focused investor scrutiny and tighter transparency demands.

iPhone Duo Spurs Carrier Hype

iPhone Duo Spurs Carrier Hype

iPhone Duo launch at $1,999 U.S. start prompts carrier promotions and raises investor questions about whether premium demand will scale.

RH Q2 Results Show Tariff Boost, Guidance Lift

RH Q2 Results Show Tariff Boost, Guidance Lift

RH Q2 Results: Management raised revenue and adjusted-EBITDA margin guidance citing RH Estates; tariff refunds lifted reported profits and aided outlooks.

Zumiez Q2 2026 Results Miss Expectations

Zumiez Q2 2026 Results Miss Expectations

Zumiez Q2 2026 results showed revenue and EPS misses as U.S. footwear softened, shifting trader focus to guidance, buybacks and balance sheet strength.

August CPI Meets Forecast; Stocks Rebound

August CPI Meets Forecast; Stocks Rebound

August CPI matched forecasts on Sept. 11 and easing oil prices helped U.S. stocks rebound as traders refocus on the Sept. 15-16 Fed rate decision.

Anthropic Claude Misuse Tied to Russia and China

Anthropic Claude Misuse Tied to Russia and China

Anthropic Claude misuse report details China distillation and Russia espionage and warns tightened controls may constrain access and raise regulatory risk.